35 research outputs found
THE INDUSTRY HAS CHANGED, HAVE YOU? THE AGCO STORY
AGCO Corporation is a success story in the agricultural machinery sector. Utilizing marketing strategies of out-sourcing, cross-over selling, and a full line of products, AGCO markets its own way. In 7 years, AGCO has 18 brands sold through 7,000 dealerships in 140 countries. Acquisition and consolidation powered the growth of AGCO using nontraditional buyout financing. Herein lies its real success.Agribusiness, Industrial Organization,
Wordless intervention for epilepsy in learning disabilities (WIELD):study protocol for a randomized controlled feasibility trial
Epilepsy is the most common neurological problem that affects people with learning disabilities. The high seizure frequency, resistance to treatments, associated skills deficit and co-morbidities make the management of epilepsy particularly challenging for people with learning disabilities. The Books Beyond Words booklet for epilepsy uses images to help people with learning disabilities manage their condition and improve quality of life. Our aim is to conduct a randomized controlled feasibility trial exploring key methodological, design and acceptability issues, in order to subsequently undertake a large-scale randomized controlled trial of the Books Beyond Words booklet for epilepsy
The impact of preoperative patient characteristics on the cost-effectiveness of total hip replacement: a cohort study
THE INDUSTRY HAS CHANGED, HAVE YOU? THE AGCO STORY
AGCO Corporation is a success story in the agricultural machinery sector. Utilizing marketing strategies of out-sourcing, cross-over selling, and a full line of products, AGCO markets its own way. In 7 years, AGCO has 18 brands sold through 7,000 dealerships in 140 countries. Acquisition and consolidation powered the growth of AGCO using nontraditional buyout financing. Herein lies its real success
Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis.
Achieving a good outcome for a person with Psoriatic Arthritis (PsA) is made difficult by late diagnosis, heterogenous clinical disease expression and in many cases, failure to adequately suppress inflammatory disease features. Single-centre studies have certainly contributed to our understanding of disease pathogenesis, but to adequately address the major areas of unmet need, multi-partner, collaborative research programmes are now required. HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centres experienced in PsA research, 5 pharmaceutical industry partners, 3 small-/medium-sized industry partners and 2 patient-representative organizations. In this review, the ambitious programme of work to be undertaken by HIPPOCRATES is outlined and common approaches and challenges are identified. It is expected that, when completed, the results will ultimately allow for changes in the approaches to diagnosing, managing and treating PsA allowing for better short-term and long-term outcomes
Regioselektive Funktionalisierung nicht aktivierter CH-Bindungen, 2. Photochemische Funktionalisierung des Myristoylrestes in 1,2-Alkandiyl- undo-Phenylen-1-(4-benzoylbenzoat)-2-myristaten
Crystal Engineering through Halogen Bonding: Complexes of Nitrogen Heterocycles with Organic Iodides
The Use and Abuse of Environmental Knowledge: A Bloomington School Interpretation of the Canadian Fisheries Act of 1868
The impact of preoperative patient characteristics on the cost-effectiveness of total hip replacement: A cohort study.
BACKGROUND: To facilitate the discussion on the increasing number of total hip replacements (THR) and their effectiveness, we apply a joint evaluation of hospital case costs and health outcomes at the patient level to enable comparative effectiveness research (CER) based on the preoperative health state. METHODS: In 2012, 292 patients from a German orthopedic hospital participated in health state evaluation before and 6 months after THR, where health-related quality of life (HRQoL) and disease specific pain and dysfunction were analyzed using EQ-5D and WOMAC scores. Costs were measured with a patient-based DRG costing scheme in a prospective observation of a cohort. Costs per quality-adjusted life year (QALY) were calculated based on the preoperative WOMAC score, as preoperative health states were found to be the best predictors of QALY gains in multivariate linear regressions. RESULTS: Mean inpatient costs of THR were 6,310 Euros for primary replacement and 7,730 Euros for inpatient lifetime costs including revisions. QALYs gained using the U.K. population preference-weighted index were 5.95. Lifetime costs per QALY were 1,300 Euros. CONCLUSIONS: The WOMAC score and the EQ-5D score before operation were the most important predictors of QALY gains. The poorer the WOMAC score or the EQ-5D score before operation, the higher the patient benefit. Costs per QALY were far below common thresholds in all preoperative utility score groups and with all underlying calculation methodologies